.New Delhi, Delhi, India
A health worker administers a dose of a COVID-19 vaccine to a woman in Uttar Pradesh's Prayagraj. (PTI Photo)

  • The vaccine uses tiny virus protein fragments and an immune-boosting substance called an adjuvant
  • The US-based company is also conducting trials of a third dose as a six-month booster
  • Novavax plans to license the vaccine to manufacturers, including Serum Institute of India

New Delhi, Jun 14 (PTI) Novavax Inc, which has a vaccine manufacturing agreement with Serum Institute of India, on Monday said its COVID-19 vaccine candidate was highly effective with 90.4 per ...

.Washington D.C., DC, USA
The Novavax vaccine has not yet been authorised in any country. (Photo Credit: PTI)

  • Far fewer children have been sick with COVID-19 compared to adults
  • Novavax said the trials would test "the efficacy (and) safety" of the vaccine
  • Participants will be monitored for up to two years after their injections

.Pune, Maharashtra, India
Covavax is the coronavirus vaccine developed by US biotech firm Novavax. (Photo Credit: Representational Image/Pixabay)

  • SII is in partnership with Novavax to develop several doses of Covavax in India
  • SII CEO Adar Poonawalla said the vaccine had an overall efficacy of 89%
  • The company is also manufacturing 'Covishield', AstraZeneca's COVID-19 vaccine

Novavax's US request maybe delayed. (Photo Credit: Representational Image/Pixabay)

  • The company has no assurance that US authorities will agree to consider the request
  • "The data will hopefully be presented to the British MHRA "by early second quarter 2021," Novavax said in a statement
  • The Novavax vaccine was 95.6% effective against the original COVID-19 strain

.Pune, Maharashtra, India
Pune-based SII is manufacturing COVID-19 vaccine, developed by AstraZeneca. (Photo Credit: AP/PTI)

  • UNICEF has entered into a supply agreement with SII for Covishield and Novavax vaccines
  • UNICEF said it'll have access to up to 1.1 billion doses of vaccines for around 100 countries
  • India is one of the world's biggest drugmakers

.Washington D.C., DC, USA
Novavax is developing a recombinant protein vaccine. (Photo Credit: Representational Image/Pixabay)

  • The new trials will include around 30,000 volunteers over the age of 18
  • Two-thirds of the participants will receive the vaccine and one-third a placebo
  • The vaccine can be stored between two and eight degrees Celsius

.Washington D.C., DC, USA
Novovax conducted its trials for the COVID-19 vaccines in Britain (Photo Credit: Representational Image/Unsplash)

  • The overall efficacy of the vaccine study in South Africa was 49.4%
  • The vaccine is 89.3% effective against the original strain
  • The work for developing a vaccine for the new variants started in early January this year